

House Bill 2515

Sponsored by COMMITTEE ON HEALTH CARE (at the request of Oregon State Pharmacy Association, Oregon State Pharmacy Coalition)

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure **as introduced**.

Requires State Board of Pharmacy to establish electronic prescription monitoring program for information reported by pharmacies regarding dispensing of certain prescription drugs. Restricts access to and limits use of reported information. Provides certain immunities from civil liability relating to reporting or use of information.

Creates Prescription Monitoring Program Advisory Commission.

Declares emergency, effective on passage.

A BILL FOR AN ACT

1
2 Relating to an electronic prescription monitoring program; and declaring an emergency.

3 Whereas the ability to identify and inhibit the diversion of prescription drugs must be improved;
4 and

5 Whereas the appropriate use of prescription drugs for legitimate medical purposes must be pro-
6 tected; and

7 Whereas the goal of this 2009 Act is to improve the ability to identify and inhibit the diversion
8 of prescription drugs, while promoting appropriate utilization of prescription drugs for legitimate
9 medical purposes; and

10 Whereas the creation and operation of an electronic system to track prescriptions of controlled
11 substances would improve the ability to identify and inhibit the diversion of prescription drugs but
12 would not adversely affect prescriptions issued for legitimate medical purposes; and

13 Whereas the purpose of this 2009 Act is to authorize the development, implementation, operation
14 and evaluation of an electronic system for the monitoring of prescription drugs to accomplish the
15 goal of this 2009 Act; now, therefore,

16 **Be It Enacted by the People of the State of Oregon:**

17 **SECTION 1. Sections 2 to 9 of this 2009 Act are added to and made a part of ORS chapter**
18 **689.**

19 **SECTION 2. As used in sections 2 to 9 of this 2009 Act:**

20 (1) "Health professional regulatory board" has the meaning given that term in ORS
21 676.160.

22 (2) "Prescription" has the meaning given that term in ORS 475.005.

23 **SECTION 3. (1)(a) The State Board of Pharmacy, in consultation with the Prescription**
24 **Monitoring Program Advisory Commission, shall establish and maintain a prescription mon-**
25 **itoring program for monitoring and reporting prescription drugs dispensed by pharmacies in**
26 **Oregon and that are drugs of concern with a documented potential for abuse.**

27 (b)(A) To fulfill the requirements of this subsection, the board shall establish, maintain
28 and operate an electronic system to monitor and report drugs of concern with a documented

NOTE: Matter in **boldfaced** type in an amended section is new; matter [*italic and bracketed*] is existing law to be omitted. New sections are in **boldfaced** type.

1 potential for abuse that are dispensed by prescription.

2 (B) Law enforcement personnel and treatment professionals may identify drugs of concern with a documented potential for abuse for inclusion in the electronic system. Persons
3 identifying drugs for inclusion in the electronic system under this paragraph shall submit
4 information relating to the drugs identified in a form and manner prescribed by the board.
5 The board shall consider information submitted under this paragraph in establishing the list
6 of drugs of concern with documented potential for abuse for monitoring and reporting in the
7 prescription monitoring program.
8

9 (C) The system must operate and be accessible by practitioners and pharmacies 24 hours
10 a day, seven days a week.

11 (D) The board may contract with a state agency or private entity to ensure the effective
12 operation of the electronic system.

13 (2) In consultation with the commission, the board shall adopt rules for the operation of
14 the electronic prescription monitoring program established under subsection (1) of this section,
15 including but not limited to standards for:

16 (a) Reporting data;

17 (b) Providing maintenance, security and disclosure of data;

18 (c) Ensuring accuracy and completeness of data;

19 (d) Complying with federal Health Insurance Portability and Accountability Act and regulations
20 thereunder, including 45 C.F.R. parts 160 and 164;

21 (e) Ensuring accurate identification of persons or entities requesting information from
22 the database;

23 (f) Assessing civil penalties for failing to report or for wrongful disclosure of data;

24 (g) Determining prescription drugs of concern with documented potential for abuse for
25 monitoring and reporting in the prescription monitoring program;

26 (h) Accepting printed or nonelectronic reports from pharmacies that do not have the
27 capability to provide electronic reports; and

28 (i) Developing and maintaining effective evaluation and referral mechanisms to evaluate
29 and refer appropriate individuals to medical care, addiction treatment or law enforcement.

30 (3) The board shall submit an annual report to the commission regarding the prescription
31 monitoring program established under this section.

32 **SECTION 4.** (1) Not later than one week after dispensing a prescription drug subject to
33 the prescription monitoring program established under section 3 of this 2009 Act, a pharmacy
34 shall electronically report to the State Board of Pharmacy the:

35 (a) Name, address and date of birth of the patient;

36 (b) Identification of the pharmacy dispensing the prescription drug;

37 (c) Identification of the practitioner who prescribed the drug;

38 (d) Identification of the prescription drug by a national drug code number;

39 (e) Date of origin of the prescription;

40 (f) Date the drug was dispensed;

41 (g) Quantity of drug dispensed; and

42 (h) Other relevant information as required by rules adopted by the board.

43 (2) Notwithstanding subsection (1) of this section, the board may not:

44 (a) Require the reporting of prescription drugs administered directly to a patient or dispensed
45 pursuant to ORS 127.800 to 127.897; or

1 (b) Collect or use Social Security numbers in the prescription monitoring program.

2 (3) Upon receipt of the data reported pursuant to subsection (1) of this section, the board
3 shall record the data in the electronic system operated pursuant to the prescription moni-
4 toring program.

5 (4)(a) The board may grant a pharmacy a waiver of the electronic submission require-
6 ment of subsection (1) of this section for good cause as determined by the board. The waiver
7 shall state the format, method and frequency of the alternate nonelectronic submissions
8 from the pharmacy and the duration of the waiver.

9 (b) As used in this subsection, "good cause" includes financial hardship.

10 **SECTION 5.** (1) Except as provided under subsection (2) of this section, prescription
11 monitoring information submitted under section 4 of this 2009 Act to the prescription moni-
12 toring program established in section 3 of this 2009 Act:

13 (a) Is protected health information under ORS 192.518 to 192.529.

14 (b) Is not subject to disclosure pursuant to ORS 192.410 to 192.505.

15 (2)(a) If prescription drug monitoring program information disclosures comply with the
16 federal Health Insurance Portability and Accountability Act and regulations thereunder, in-
17 cluding 45 C.F.R. parts 160 and 164, the State Board of Pharmacy may disclose the informa-
18 tion:

19 (A) To a practitioner or pharmacist who certifies that the requested information is for
20 the purpose of evaluating the need for or providing medical or pharmaceutical treatment for
21 a patient to whom the practitioner or pharmacist anticipates providing, is providing or has
22 provided care.

23 (B) To designated representatives of the board or any vendor or contractor with whom
24 the board has contracted to establish or maintain the electronic system of the prescription
25 monitoring program.

26 (C) Pursuant to a valid court order issued at the request of a federal, state or local law
27 enforcement agency engaged in an authorized drug-related investigation involving a person
28 to whom the requested information pertains.

29 (D) To a health professional regulatory board that certifies that the requested informa-
30 tion is necessary for an investigation related to licensure, renewal or disciplinary action in-
31 volving the applicant, licensee or registrant to whom the requested information pertains.

32 (E) To a prescription monitoring program of another state if the confidentiality, security
33 and privacy standards of the requesting state are determined by the board to be equivalent
34 to those of the board.

35 (b) Information from the prescription monitoring program that does not identify a pa-
36 tient, practitioner or drug outlet may be released by the board for educational, research or
37 public information purposes.

38 (c) Information relating to a patient may be disclosed to that patient if requested in ac-
39 cordance with procedures established by the board. The information shall be disclosed to the
40 patient within 10 business days of the request being received by the board, and the patient
41 may make a request to the board up to once every six months. A patient may request the
42 board to correct any information about the patient that is erroneous.

43 (d) In accordance with ORS 192.518 to 192.529 and federal privacy regulations, any person
44 authorized to prescribe or dispense a prescription drug and who is entitled to access a pa-
45 tient's prescription monitoring program information may discuss or release the information

1 to other health care providers involved with the patient's care, in order to provide safe and
 2 appropriate care coordination.

3 (3)(a) The board shall maintain records of the information disclosed through the pre-
 4 scription monitoring program including, but not limited to:

5 (A) The identification of each person who requests or receives information from the
 6 program and the organization, if any, the person represents;

7 (B) The information released to each person or organization; and

8 (C) The date and time the information was requested and the date and time the infor-
 9 mation was provided.

10 (b) Records maintained as required by this subsection may be reviewed by the Pre-
 11 scription Monitoring Program Advisory Commission.

12 (4) Information in the prescription monitoring program that identifies an individual pa-
 13 tient must be removed no later than three years from the date the information is entered
 14 into the program.

15 (5) A pharmacy required to report information to the board, or a person authorized under
 16 this section to obtain or use information from the prescription monitoring program estab-
 17 lished under section 3 of this 2009 Act, is immune from civil liability arising out of the re-
 18 porting or release of the information if the pharmacy or person reports, obtains or uses the
 19 data in good faith.

20 (6) The board and the commission are immune from civil liability arising from the inac-
 21 curacy of any information submitted under section 4 of this 2009 Act to the prescription
 22 monitoring program.

23 (7) Nothing in sections 2 to 9 of this 2009 Act requires a practitioner or pharmacist who
 24 prescribes or dispenses a prescription drug to obtain information about a patient from the
 25 prescription monitoring program. A practitioner or pharmacist who prescribes or dispenses
 26 a prescription drug may not be held liable for damages in any civil action on the basis that
 27 the practitioner or pharmacist did or did not request or obtain information from the pre-
 28 scription monitoring program.

29 **SECTION 6.** (1) A practitioner may not refuse to provide a prescription to a patient solely
 30 because the practitioner cannot receive information from the prescription monitoring pro-
 31 gram established under section 3 of this 2009 Act at the time the practitioner would other-
 32 wise have provided the patient a prescription.

33 (2) A pharmacist may not refuse to fill a valid prescription solely because the pharmacist
 34 cannot receive patient information from the prescription monitoring program established
 35 under section 3 of this 2009 Act at the time the patient requests that the prescription be
 36 filled.

37 **SECTION 7.** (1) The State Board of Pharmacy may accept grants, donations, gifts or
 38 moneys from any source for expenditures consistent with the purposes of sections 2 to 9 of
 39 this 2009 Act.

40 (2) Notwithstanding ORS 689.135, the board may impose on practitioners authorized to
 41 prescribe or dispense controlled substances an annual fee not to exceed \$25 for expenditures
 42 consistent with the proposes of sections 2 to 9 of this 2009 Act.

43 (3) Any moneys received under this section shall be paid into the State Treasury and
 44 credited to the State Board of Pharmacy Account.

45 (4) As used in this section, "controlled substance" has the meaning given that term in

1 **ORS 475.005.**

2 **SECTION 8. (1) The Prescription Monitoring Program Advisory Commission is created**
3 **for the purposes of:**

4 (a) Studying issues related to the prescription monitoring program established under
5 section 3 of this 2009 Act;

6 (b) Reviewing the program's annual report and making recommendations to the State
7 Board of Pharmacy regarding the operation of the program; and

8 (c) Developing criteria that should be used to evaluate program data.

9 (2)(a) The commission shall consist of 14 members appointed by the board, one member
10 nominated by each of the following:

11 (A) Pain Management Commission;

12 (B) Oregon State Pharmacy Association;

13 (C) Oregon Dental Association;

14 (D) Oregon Medical Association;

15 (E) Oregon Nurses Association;

16 (F) Oregon Association of Naturopathic Physicians;

17 (G) Oregon Board of Dentistry;

18 (H) Oregon Medical Board;

19 (I) Board of Naturopathic Examiners;

20 (J) Oregon State Board of Nursing;

21 (K) State Board of Pharmacy;

22 (L) Department of State Police;

23 (M) A health professional licensing board that regulates addiction counselors; and

24 (N) Department of Human Services.

25 (b) The member nominated by the Department of Human Services must have expertise
26 as an addiction treatment professional.

27 **SECTION 9. (1) The term of office of each member of the Prescription Monitoring Pro-**
28 **gram Advisory Commission is four years, but a member serves at the pleasure of the State**
29 **Board of Pharmacy. Before the expiration of the term of a member, the board shall appoint**
30 **a successor whose term begins on July 1 next following. A member is eligible for reappoint-**
31 **ment. If there is a vacancy for any cause, the board shall make an appointment to become**
32 **immediately effective.**

33 (2) The commission shall elect one of its members to serve as chairperson.

34 (3) The commission shall meet at least once annually at a time and place specified by the
35 chairperson of the commission. The commission may meet at other times and places speci-
36 fied by the call of the chairperson or of a majority of the members of the commission.

37 (4) The commission may adopt rules necessary for the operation of the commission.

38 (5) A majority of the members of the commission constitutes a quorum for the trans-
39 action of business.

40 (6) Official action by the commission requires the approval of a majority of the members
41 of the commission.

42 (7) The board shall provide staff support to the commission.

43 (8) Members of the commission who are not members of the Legislative Assembly are
44 not entitled to compensation, but may be reimbursed for actual and necessary travel and
45 other expenses incurred by them in the performance of their official duties in the manner

1 and amounts provided for in ORS 292.495. Claims for expenses incurred in performing func-
2 tions of the commission shall be paid out of funds appropriated to the board for that purpose.

3 (9) All agencies of state government, as defined in ORS 174.111, are directed to assist the
4 commission in the performance of its duties and, to the extent permitted by laws relating
5 to confidentiality, to furnish such information and advice as the members of the commission
6 consider necessary to perform their duties.

7 **SECTION 10.** Notwithstanding the term of office specified by section 9 of this 2009 Act,
8 the members first appointed to the Prescription Monitoring Program Advisory Commission
9 shall determine by lot at the first meeting of the commission the initial terms of office for
10 commission members as follows:

11 (1) Four shall serve for a term ending July 1, 2010.

12 (2) Five shall serve for a term ending on July 1, 2011.

13 (3) Five shall serve for a term ending on July 1, 2012.

14 **SECTION 11.** (1) Sections 4 to 6 of this 2009 Act become operative on January 1, 2010.

15 (2) The State Board of Pharmacy may take any action before the operative date specified
16 in subsection (1) of this section that is necessary to enable the board to exercise, on or after
17 the operative date specified in subsection (1) of this section, all of the duties, functions and
18 powers conferred on the board by sections 4 to 6 of this 2009 Act.

19 **SECTION 12.** This 2009 Act being necessary for the immediate preservation of the public
20 peace, health and safety, an emergency is declared to exist, and this 2009 Act takes effect
21 on its passage.